Ixabepilone
Alveolar Childhood Rhabdomyosarcoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Alveolar Childhood Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACTINOMYCIN Children's Oncology Group | Phase 3 | B |
Cyclophosphamide Children's Oncology Group | Phase 3 | B |
Vinorelbine Children's Oncology Group | Phase 3 | B |
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | B |
Crizotinib European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | B |
View all 9 →
Same molecule, other indications
Ixabepilone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →